Radiopharmaceutical Cardiolite has 15 Percent More Market Share than Myoview for September 2008

Administration of Astellas's Lexiscan in Patients Increased by 58 Percent From August to September 2008, According To New Data from Arlington Medical Resources

MALVERN, Pa., Nov. 11 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that Lantheus Medical Imaging's Cardiolite has 15 percent more market share than General Electric's Myoview for September 2008. Both Cardiolite and Myoview are administered intravenously as part of the Myocardial Perfusion Imaging Stress Test to highlight areas of the heart. The Myocardial Perfusion Imaging Stress Test is given to help diagnose coronary artery disease.

"Compared to data from our September 2007 audit, Cardiolite use has dropped nine percent. Even so, Cardiolite continues to dominate the radiopharmaceutical market," stated Anna Fisher, analyst at AMR.

The newly released edition of the Myocardial Perfusion Study Monthly Monitor also finds the number of patients who were administered Astellas's Lexiscan (regadenoson) increased 58.5 percent from August 2008 to September 2008. Lexiscan is the newest pharmacologic stress agent on the market--introduced in June 2008--and it is used in patients unable to undergo exercise stress testing.

Why Pharmaceutical and Medical Device Companies Need this Information

The Myocardial Perfusion Study Monthly Monitor enables pharmaceutical and medical device companies to track the number of nuclear myocardial perfusion tests performed in hospital and non-hospital settings. For each study month, this audit provides projections of myocardial perfusion studies performed with each of the various radiopharmaceutical products. Projections are also provided for the number of studies involving pharmacologic stressing with intravenous adenosine, intravenous dipyridamole, intravenous regadenoson and intravenous dobutamine.

About the Myocardial Perfusion Study Monthly Monitor AMR's Myocardial Perfusion Study Monthly Monitor is a syndicated audit designed to track the number of nuclear myocardial perfusion tests performed in hospital and non-hospital settings. The audit is available once a month.

About AMR

AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Natalia Morales                           Elizabeth Marshall
    Decision Resources                        Decision Resources, Inc.
    781-296-2691                              781-296-2563
    nmorales@dresources.com                   emarshall@dresources.com

SOURCE Arlington Medical Resources